Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Cardiovascular Diabetology

Volumn 17, Issue 1, 2018, Pages

  Aroor, Annayya R ^a,b   Das, Nitin A ^c   Carpenter, Andrea J ^c   Habibi, Javad ^a,b   Jia, Guanghong ^a,b   Ramirez Perez, Francisco I ^e   Martinez Lemus, Luis ^e,f   Manrique Acevedo, Camila M ^a,b   Hayden, Melvin R ^a   Duta, Cornel ^a,b   Nistala, Ravi ^a,b   Mayoux, Eric ^d   Padilla, Jaume ^a,e   Chandrasekar, Bysani ^a,b,e,f   DeMarco, Vincent G ^a,b,f  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

Author keywords

Pulsatility index; RECK; Renal resistivity; SGLT2; Vascular stiffness

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARRIER PROTEIN; EMPAGLIFLOZIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; RECK PROTEIN, MOUSE; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC ENDOTHELIAL CELL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INFANT; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PULSATILITY INDEX; RESISTIVE INDEX; VASODILATATION; ALBUMINURIA; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; COMPLICATION; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; KIDNEY; KIDNEY CIRCULATION; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; PULSATILE FLOW; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASCULARIZATION;

ALBUMINURIA; ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSIDES; GLYCOSURIA; GPI-LINKED PROTEINS; HUMANS; KIDNEY; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PULSATILE FLOW; RENAL CIRCULATION; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VASCULAR RESISTANCE; VASCULAR STIFFNESS; VASODILATION;

EID: 85050775181     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-018-0750-8     Document Type: Article

References (68)

1. Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.
2. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73-81.
3. Lytvyn Y, Bjornstad P, Pun N, Cherney DZ. New and old agents in the management of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2016;25(3):232-9.
4. Prenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis. 2015;238(2):370-9.
5. Calabia J, Torguet P, Garcia I, Martin N, Mate G, Marin A, Molina C, Valles M. The relationship between renal resistive index, arterial stiffness, and atherosclerotic burden: the link between macrocirculation and microcirculation. J Clin Hypertens (Greenwich). 2014;16(3):186-91.
6. Briet M, Pierre B, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012;82(4):388-400.
7. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol. 2008;105(5):1652-60.
8. Woodard T, Sigurdsson S, Gotal JD, Torjesen AA, Inker LA, Aspelund T, Eiriksdottir G, Gudnason V, Harris TB, Launer LJ, et al. Mediation analysis of aortic stiffness and renal microvascular function. J Am Soc Nephrol. 2015;26(5):1181-7.
9. Zhang J, Bottiglieri T, McCullough PA. The central role of endothelial dysfunction in cardiorenal syndrome. Cardiorenal Med. 2017;7(2):104-17.
10. Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011;58(5):839-46.
11. Boddi M, Natucci F, Ciani E. The internist and the renal resistive index: truths and doubts. Intern Emerg Med. 2015;10(8):893-905.
12. Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, Ghamdi SSA. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother. 2018;103:59-66.
13. Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16(1):65.
14. Aroor AR, Manrique-Acevedo C, DeMarco VG. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovasc Diabetol. 2018;17(1):59.
15. Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860-70.
16. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11-26.
17. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-4.
18. Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017;241:450-6.
19. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57.
20. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-72.
21. Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K, Utsunomiya K. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083. https://doi.org/10.3390/ijms18051083.
22. Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, et al. Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study. Curr Vasc Pharmacol. 2018. https://doi.org/10.2174/1570161116666180515154555.
23. Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K, For, on behalf of Primary Care Diabetes E. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12(3):265-83.
24. Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138.
25. Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20:1988-93.
26. Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29.
27. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094.
28. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180-93.
29. Striepe K, Jumar A, Ott C, Karg MV, Schneider MP, Kannenkeril D, Schmieder RE. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136(12):1167-9.
30. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B. Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol. 2013;65:9-18.
31. Somanna NK, Valente AJ, Krenz M, McDonald KS, Higashi Y, Noda M, Chandrasekar B. Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate Angiotensin II-induced cardiac fibroblast migration and proliferation. Hypertens Res. 2016;39(10):709-16.
32. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107(6):789-800.
33. Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65(2):114-23.
34. DeMarco VG, Habibi J, Jia G, Aroor AR, Ramirez-Perez FI, Martinez-Lemus LA, Bender SB, Garro M, Hayden MR, Sun Z, et al. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66:99-107.
35. Manrique C, Demarco VG, Aroor AR, Mugerfeld I, Garro M, Habibi J, Hayden MR, Sowers JR. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a western diet. Endocrinology. 2013;154(10):3632-42.
36. Hartley CJ, Taffet GE, Michael LH, Pham TT, Entman ML. Noninvasive determination of pulse-wave velocity in mice. Am J Physiol. 1997;273(1 Pt 2):H494-500.
37. Manrique C, Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Martinez-Lemus LA, Ramirez-Perez FI, Klein T, et al. Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovasc Diabetol. 2016;15(1):94.
38. Padilla J, Ramirez-Perez FI, Habibi J, Bostick B, Aroor AR, Hayden MR, Jia G, Garro M, DeMarco VG, Manrique C, et al. Regular exercise reduces endothelial cortical stiffness in western diet-fed female mice. Hypertension. 2016;68(5):1236-44.
39. Xiao H, Butlin M, Tan I, Avolio A. Effects of cardiac timing and peripheral resistance on measurement of pulse wave velocity for assessment of arterial stiffness. Sci Rep. 2017;7(1):5990.
40. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.
41. Padilla J, Carpenter A, Das ND, Kandikattu HK, Lopez-Ongil S, Martinez-Lemus LA, Siebenlist U, DeMarco VG, Chandrasekar B. TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells. Am J Physiol Heart Circ Physiol. 2017. https://doi.org/10.1152/ajpheart.00478.2017.
42. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol CJASN. 2008;3(3):691-8.
43. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101-8.
44. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003;14(5):1383-95.
45. Gilbert RE. SGLT2 inhibitors: beta blockers for the kidney? Lancet Diabetes Endocrinol. 2016;4(10):814.
46. Sano M. Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. J Clin Med Res. 2017;9(6):457-60.
47. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, Hebert RL, Lai V, Scholey JW, Sochett EB. Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2012;303(7):R710-8.
48. Pierce GL. Recent advances: mechanisms and subclinical consequences of aortic stiffness. Hypertension. 2017;70:848-53.
49. Pofi R, Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK, Giannakakis K, Morano S, et al. Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Sci Rep. 2017;7:44584.
50. Rohatgi R, Flores D. Intratubular hydrodynamic forces influence tubulointerstitial fibrosis in the kidney. Curr Opin Nephrol Hypertens. 2010;19(1):65-71.
51. Wells RG. Tissue mechanics and fibrosis. Biochim Biophys Acta. 2013;1832(7):884-90.
52. Wang-Rosenke Y, Neumayer HH, Peters H. NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target. Curr Med Chem. 2008;15(14):1396-406.
53. Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS ONE. 2014;9(11):e108994.
54. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597-605.
55. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610-21.
56. Steven S, Oelze M, Hanf A, Kroller-Schon S, Kashani F, Roohani S, Welschof P, Kopp M, Godtel-Armbrust U, Xia N, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370-85.
57. Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem. 2017;292(13):5335-48.
58. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016;6:26428.
59. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148.
60. Aroor AR, Jia G, Habibi J, Sun Z, Ramirez-Perez FI, Brady B, Chen D, Martinez-Lemus LA, Manrique C, Nistala R, et al. Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. Metabolism. 2017;74:32-40.
61. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, et al. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension. 2013;62:1105-10.
62. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ. Investigators E-RMT: empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-9.
63. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, Investigators E-RPt. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147-58.
64. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC. Investigators E-RMT: empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396-404.
65. Dubroca C, Pilette C, Sulpice T, Mayoux E. Absence of direct effect of the sodium-glucose co-transporter inhibitors on vascular reactivity on diabetic and diabetic rodents. Diabetes. 2016;65(supplement 1):A300.
66. Khemais-Benkhiat S, Idris-Khodja N, Park S, Amoura L, Abbas M, Auger C, Kessler L, Mayoux E, Toti F, Schini-Kerth VB. Upregulation of SGLT2 expression mediates the high glucose-induced premature endothelial cell senescence and acquisition of pro-atherothrombotic markers via the activation of the local angiotensin system. In: Eur Soc Vasc Biomaterials. Strasbourg, FR; 2017.
67. Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr. 2018. https://doi.org/10.1016/j.dsx.2018.06.003.
68. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018. https://doi.org/10.1016/j.kint.2017.12.027.